STERIS plc $STE Shares Acquired by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. boosted its holdings in STERIS plc (NYSE:STE) by 3.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,237 shares of the medical equipment provider’s stock after acquiring an additional 2,087 shares during the quarter. GHP Investment Advisors Inc. owned 0.07% of STERIS worth $16,390,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in STERIS by 1.7% in the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock worth $2,921,827,000 after purchasing an additional 205,276 shares during the period. State Street Corp lifted its stake in shares of STERIS by 2.4% in the 2nd quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock worth $1,006,069,000 after acquiring an additional 98,220 shares during the period. Geode Capital Management LLC boosted its holdings in shares of STERIS by 1.9% in the second quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock valued at $592,980,000 after acquiring an additional 46,859 shares in the last quarter. Orbis Allan Gray Ltd increased its stake in shares of STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after acquiring an additional 556,088 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of STERIS by 3.9% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,346,039 shares of the medical equipment provider’s stock valued at $323,345,000 after acquiring an additional 50,764 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and an average price target of $273.50.

Insider Buying and Selling at STERIS

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares in the company, valued at $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the completion of the transaction, the vice president directly owned 10,710 shares in the company, valued at approximately $2,806,020. This trade represents a 31.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 25,044 shares of company stock valued at $6,586,218. 1.07% of the stock is currently owned by corporate insiders.

STERIS Trading Down 0.6%

STERIS stock opened at $259.44 on Friday. The firm has a market cap of $25.46 billion, a price-to-earnings ratio of 37.28 and a beta of 1.03. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The firm’s 50 day moving average price is $258.84 and its two-hundred day moving average price is $247.46. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same period last year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, research analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.0%. The ex-dividend date was Tuesday, November 18th. STERIS’s payout ratio is presently 36.21%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.